20
Participants
Start Date
February 29, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Intravenous immunoglobulin
Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
Placebo
Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
Oslo University Hospital
OTHER
University Hospital of North Norway
OTHER
University Hospital of Saint-Etienne
OTHER
Sorlandet Hospital HF
OTHER_GOV